• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为自然杀伤细胞免疫治疗的靶点的腺苷能信号。

Adenosinergic signaling as a target for natural killer cell immunotherapy.

机构信息

Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, USA.

Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, USA.

出版信息

J Mol Med (Berl). 2018 Sep;96(9):903-913. doi: 10.1007/s00109-018-1679-9. Epub 2018 Aug 1.

DOI:10.1007/s00109-018-1679-9
PMID:30069747
Abstract

Purinergic signaling through adenosine plays a key role in immune regulation. Hypoxia-driven accumulation of extracellular adenosine results in the generation of an immunosuppressive niche that fuels tumor development. Such immunometabolic modulation has shown to be a promising therapeutic target through blockade of adenosine receptors which mediate adenosine's immunosuppressive function, or cancer-associated ectonucleotidases CD39 and CD73 that catalyze the synthesis of adenosine. Adenosinergic signaling heavily implicates natural killer cells through both direct and indirect effects on their cytolytic activity, expression of cytotoxic granules, interferon-γ, and activating receptors. Continuing work has uncovered multiple checkpoints linked to adenosine within the purinergic signaling cascade as contributing to immune evasion from NK cell effector function. Here, we discuss these checkpoints and the recent body of work that focuses on adenosinergic signaling as a target for natural killer cell of cancer.

摘要

嘌呤能信号通过腺苷在免疫调节中起着关键作用。缺氧驱动的细胞外腺苷积累导致产生免疫抑制小生境,从而促进肿瘤发展。这种免疫代谢调节已被证明是一种有前途的治疗靶点,通过阻断腺苷受体来介导腺苷的免疫抑制功能,或通过催化腺苷合成的肿瘤相关胞外核苷酸酶 CD39 和 CD73。通过对自然杀伤细胞的细胞毒性活性、细胞毒性颗粒、干扰素-γ和激活受体的直接和间接影响,腺苷能信号强烈牵连自然杀伤细胞。不断的研究揭示了嘌呤能信号级联中的多个与腺苷相关的检查点,这些检查点有助于自然杀伤细胞逃避效应功能。在这里,我们讨论这些检查点以及最近的研究工作,重点关注作为癌症自然杀伤细胞靶点的腺苷能信号。

相似文献

1
Adenosinergic signaling as a target for natural killer cell immunotherapy.作为自然杀伤细胞免疫治疗的靶点的腺苷能信号。
J Mol Med (Berl). 2018 Sep;96(9):903-913. doi: 10.1007/s00109-018-1679-9. Epub 2018 Aug 1.
2
Purinergic targeting enhances immunotherapy of CD73 solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells.嘌呤能靶向增强猪源 Bac 工程嵌合抗原受体自然杀伤细胞治疗 CD73 实体瘤的免疫疗法。
J Immunother Cancer. 2018 Dec 4;6(1):136. doi: 10.1186/s40425-018-0441-8.
3
Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).腺苷对T细胞和自然杀伤细胞功能的抑制及其对肿瘤细胞免疫逃逸的作用(综述)
Int J Oncol. 2008 Mar;32(3):527-35.
4
Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells.肿瘤微环境诱导自然杀伤细胞的免疫代谢重编程。
Front Immunol. 2018 Nov 8;9:2517. doi: 10.3389/fimmu.2018.02517. eCollection 2018.
5
Adenosinergic Signaling Alters Natural Killer Cell Functional Responses.腺苷信号转导改变自然杀伤细胞的功能反应。
Front Immunol. 2018 Oct 30;9:2533. doi: 10.3389/fimmu.2018.02533. eCollection 2018.
6
Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.工程化自然杀伤细胞抑制实体瘤中的免疫代谢 CD73-腺苷轴。
Elife. 2022 Jul 11;11:e73699. doi: 10.7554/eLife.73699.
7
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.靶向癌症免疫疗法中的腺苷以增强 T 细胞功能。
Front Immunol. 2019 Jun 6;10:925. doi: 10.3389/fimmu.2019.00925. eCollection 2019.
8
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.靶向肿瘤免疫治疗中的腺苷受体信号通路
Int J Mol Sci. 2018 Dec 2;19(12):3837. doi: 10.3390/ijms19123837.
9
Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?腺苷信号:胃癌免疫治疗的下一个检查点?
Int Immunopharmacol. 2018 Oct;63:58-65. doi: 10.1016/j.intimp.2018.07.023. Epub 2018 Jul 31.
10
Targeting adenosine for cancer immunotherapy.针对癌症免疫疗法的腺苷靶点。
J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8.

引用本文的文献

1
Tumor hypoxia shapes natural killer cell anticancer activities.肿瘤缺氧塑造自然杀伤细胞的抗癌活性。
J Mol Med (Berl). 2025 May 30. doi: 10.1007/s00109-025-02557-6.
2
Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer.Axl对自然杀伤细胞活性的调控在头颈癌中营造了一个免疫抑制性肿瘤免疫微环境。
Cancers (Basel). 2025 Mar 15;17(6):994. doi: 10.3390/cancers17060994.
3
Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes.

本文引用的文献

1
Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.调控免疫抑制剂:调节 CD73/NT5E 的转录因子和 microRNAs。
Front Immunol. 2018 Apr 18;9:813. doi: 10.3389/fimmu.2018.00813. eCollection 2018.
2
ATP Release Channels.ATP 释放通道。
Int J Mol Sci. 2018 Mar 11;19(3):808. doi: 10.3390/ijms19030808.
3
The hypoxic tumour microenvironment.缺氧肿瘤微环境
自然杀伤细胞对缺氧的适应性:转录、翻译及代谢过程综述
Immunotargets Ther. 2025 Feb 18;14:99-121. doi: 10.2147/ITT.S492334. eCollection 2025.
4
CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies.治疗诱导性肺炎中的CD73/腺苷动力学:在联合放射免疫疗法中平衡疗效与不良事件风险
Front Cell Dev Biol. 2025 Jan 13;12:1471072. doi: 10.3389/fcell.2024.1471072. eCollection 2024.
5
The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer.嘌呤能信号在癌症治疗中的潜在作用:前列腺癌抗CD73策略的前景
Front Immunol. 2024 Sep 17;15:1455469. doi: 10.3389/fimmu.2024.1455469. eCollection 2024.
6
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.代谢重编程与免疫逃逸:肿瘤微环境中的相互作用
Biomark Res. 2024 Sep 3;12(1):96. doi: 10.1186/s40364-024-00646-1.
7
Hypoxic tumor microenvironment: Destroyer of natural killer cell function.缺氧肿瘤微环境:自然杀伤细胞功能的破坏者。
Chin J Cancer Res. 2024 Apr 30;36(2):138-150. doi: 10.21147/j.issn.1000-9604.2024.02.04.
8
Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation.嘌呤能受体在治疗调节中的药物相互作用和免疫反应。
Purinergic Signal. 2024 Aug;20(4):321-343. doi: 10.1007/s11302-023-09966-7. Epub 2023 Oct 16.
9
The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.腺苷在肿瘤微环境中的免疫调节作用。
Int J Mol Sci. 2023 Oct 5;24(19):14928. doi: 10.3390/ijms241914928.
10
Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.靶向免疫抑制性腺苷信号:潜在免疫治疗联合策略的综述。
Int J Mol Sci. 2023 May 17;24(10):8871. doi: 10.3390/ijms24108871.
Oncogenesis. 2018 Jan 24;7(1):10. doi: 10.1038/s41389-017-0011-9.
4
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.腺苷信号传导介导慢性淋巴细胞白血病微环境中的缺氧反应。
Blood Adv. 2016 Nov 22;1(1):47-61. doi: 10.1182/bloodadvances.2016000984. eCollection 2016 Nov 29.
5
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.A2AR 腺苷信号抑制肿瘤微环境中自然杀伤细胞的成熟。
Cancer Res. 2018 Feb 15;78(4):1003-1016. doi: 10.1158/0008-5472.CAN-17-2826. Epub 2017 Dec 11.
6
Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.细胞外三磷酸腺苷和腺苷在肿瘤-宿主相互作用中的多方面影响及治疗前景
Front Immunol. 2017 Nov 14;8:1526. doi: 10.3389/fimmu.2017.01526. eCollection 2017.
7
Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis.自然杀伤细胞中 HIF-1α 的缺失通过刺激非生产性血管生成抑制肿瘤生长。
Nat Commun. 2017 Nov 17;8(1):1597. doi: 10.1038/s41467-017-01599-w.
8
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.三阴性乳腺癌中 CD73 的临床意义:III 期临床试验的多重分析。
Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.
9
Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.携带免疫抑制性货物的循环外泌体干扰急性髓系白血病的细胞免疫治疗。
Sci Rep. 2017 Oct 31;7(1):14684. doi: 10.1038/s41598-017-14661-w.
10
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.基因工程改造人自然杀伤细胞表达 CXCR2 可改善其向肾细胞癌的迁移。
J Immunother Cancer. 2017 Sep 19;5(1):73. doi: 10.1186/s40425-017-0275-9.